AstraZeneca's Imfinzi cuts muscle-invasive bladder cancer death risk 42% in Volga trial

AstraZeneca's Imfinzi (durvalumab) reduced the risk of death by 42% in muscle-invasive bladder cancer patients in the Volga trial, according to a report.

Detected & updated continuously · Source: Nebula